Prescription Prices and Coupons from GoodRx
Type your drug name (like Atorvastatin, Sildenafil, etc)
Epclusa Coupon - Epclusa 28 tablets of 400mg/100mg bottle
Velpatasvir and Sofosbuvir
Specialty Drug
SOFOSBUVIR; VELPATASVIR (soe fos' bue veer; vel pat' us veer) is an antiviral medicine. It is used with other medicines to treat hepatitis C. It will not work for colds, flu, or other viral infections. The lowest GoodRx price for the most common version of Epclusa is around $24,754.11, -18% off the average retail price of $21,045.84. Compare nucleotide polymerase / NS5A inhibitor combinations.
Prescription Settings
28 tablets of 400mg/100mg
1 bottle
Epclusa Coupon - Epclusa 28 tablets of 400mg/100mg bottle
28 tablets of 400mg/100mg
1 bottle

Velpatasvir and Sofosbuvir Latest News

Get the latest updates on this drug from the GoodRx medical team

How To Save on Harvoni, One of the Most Expensive Drugs in the US

Tori Marsh
Tori Marsh -

Treatments for hepatitis C are notoriously expensive, and the price for Harvoni is no different. Patients typically take Harvoni for 12 weeks, and the list price for a one-month supply runs at $31,500 for 28 tablets—or $1,125 per tablet—making Harvoni the ninth most expensive drug in the United States. We’re not kidding.

Harvoni’s manufacturer, Gilead, just announced that they will soon be releasing an authorized generic for Harvoni. See More

FDA Safety Alert: Direct-Acting Antivirals for Hepatitis C

Roni Shye
Roni Shye -

The FDA has issued a drug safety alert for direct-acting antivirals used to treat Hepatitis C. They warn that using direct-acting antivirals such as Sovaldi, Harvoni, or Zepatier can cause a reactivation of Hepatitis B in patients who have been previously infected with the virus.

The FDA gained knowledge about the reactivation of hepatitis B occurring from direct-acting antivirals through reported incidents and published literature. See More

New Hepatitis C Med Epclusa Now Approved

Roni Shye
Roni Shye -

More and more new hepatitis C medications are being approved at a faster rate than ever thanks to the FDA’s Priority Review program. New approvals over the past few years include Sovaldi, Harvoni, Viekira Pak.

This is great news, as it means there are more effective options than ever out there to treat hepatitis C—and the most recent addition, Epclusa (sofosbuvir/velpatasvir), is another first of its kind treatment. See More

Copyright ©2018 GoodRx, Inc.
GoodRx is not sponsored by or affiliated with any of the pharmacies identified in its price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders and are used solely to represent the products of these rights holders. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment.
In all states except Tennessee, GoodRx is considered a marketer of prescription discount cards, and is not required to register as a discount card provider. In Tennessee, GoodRx is registered as a Prescription Drug Discount Plan Operator.
LegitScript SealNABP SealBBB Seal